Biotechnology

Monday Mar 04, 2024 - 1:35 pm

InvestorNewsBreaks – BioVie Inc. (NASDAQ: BIVI) to Secure ~$21M in Public Offering

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. The company today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price…

Friday Mar 01, 2024 - 3:21 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other…

Friday Mar 01, 2024 - 3:05 pm

InvestorNewsBreaks – Astiva Health Redefining the Standards of Personalized and Comprehensive Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, is one of the companies committed to providing robust and stable benefit offerings to a growing number of people looking for the best Medicare options. “In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage…

Friday Mar 01, 2024 - 2:06 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according…

Thursday Feb 29, 2024 - 12:12 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Planned Participation at MIXiii 2024, Bio Europe Spring Conference

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced that it will be attending the MIXiii International Life Science and Health-tech Conference. The event is slated to take place March 5 and 6 in Jerusalem. Several members of Scinai’s leadership team will be available for discussions…

Thursday Feb 29, 2024 - 10:00 am

InvestorNewsBreaks – Ocean Biomedical Inc.’s (NASDAQ: OCEA) Joint Venture Partner to Present First Clinical Study Data at 33rd Annual Meeting of APASL

Ocean Biomedical (NASDAQ: OCEA), a biopharma company that endeavors to accelerate the development of compelling discoveries from top research scientists, congratulates its joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing T cell-based immunotherapies, for the acceptance of its abstract highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure. The abstract was accepted for late breaker oral…

Thursday Feb 29, 2024 - 9:52 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented…

Wednesday Feb 28, 2024 - 10:33 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced a debt settlement. According to the announcement, the company’s board of directors approved the settlement of $637,650 owed to arm's length creditors through issuing 545,000 Class B subordinate voting shares in the capital of the corporation; the shares were issued at…

Wednesday Feb 28, 2024 - 9:00 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results, Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million with grant revenue for 2023 being less than $0.1 million; related cost of revenues was $0.5 million for 2023; and gross profit…

Tuesday Feb 27, 2024 - 3:09 pm

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of…

Monday Feb 26, 2024 - 11:41 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and its subsidiary, HUGE Biopharma Australia Pty Ltd., have entered into an agreement with Ingenu CRO Pty Ltd. The agreement outlines a study to assess the safety and efficacy of unbuzzd(TM), a fortified oral liquid formula, being used as a treatment with healthy…

Thursday Feb 22, 2024 - 12:45 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today reported new, significant survival results in amyotrophic lateral sclerosis (“ALS”) patients. According to the announcement, the results are from two independent analyses of pooled data from two intermediate-size “Companionate Use” Expanded…

Thursday Feb 22, 2024 - 9:21 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results, Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The company announced that it will release its 2023 financial results after market close on Feb. 27, 2024, and will host a conference call at 5 p.m. ET that same day. During the call, company officials will provide an…

Wednesday Feb 21, 2024 - 3:11 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Bringing ‘Game Changer’ Technology in AgLAB MVP

Astrotech’s (NASDAQ: ASTC) subsidiary AgLAB, Inc. has breakthrough mass spectrometry technology in its AgLAB 1000-D2 mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%. Large-scale CBD and THC oil processors use molecular distillation systems (‘MDS’) to produce the valuable…

Wednesday Feb 21, 2024 - 2:07 pm

InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients

Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The…

Wednesday Feb 21, 2024 - 1:19 pm

InvestorNewsBreaks – Modular Medical Inc. (NASDAQ: MODD) Announces Pricing of $10M Public Offering

Modular Medical (NASDAQ: MODD), a development-stage insulin delivery technology company seeking to launch the next generation of easy-to-use and affordable insulin pump technology, previously announced the pricing of its underwritten public offering of 9,090,910 shares of its common stock. The offering is led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s chief executive officer, Morgan Frank, a member of the company’s…

Tuesday Feb 20, 2024 - 3:13 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements…

Tuesday Feb 20, 2024 - 10:27 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the capital of the company at its discretion. The offering may…

Tuesday Feb 20, 2024 - 9:45 am

InvestorNewsBreaks — Astiva Health Opens Doors to New LA-Koreatown Activity Center, Marks ‘Testament’ to Empowering Seniors

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, has opened a new facility in Los Angeles. The company is celebrating the Dec. 16, 2023, opening of its Los Angeles-Koreatown Activity Center. The grand-opening ceremony, which marked a milestone for Astiva in its efforts to serve the senior community of Koreatown, included a ribbon cutting by…

Thursday Feb 15, 2024 - 1:43 pm

InvestorNewsBreaks – Datasea Inc. (NASDAQ: DTSS) Collaborates to Bring Unique Platform to New Customers

Datasea (NASDAQ: DTSS) is a Nevada incorporated digital technology corporation engaged in innovative business segments for intelligent acoustics and 5G multimodal communication technology in China. The company has announced that on Feb. 2, 2024, Guozhong Times (Beijing) Technology Ltd., a subsidiary of the Chinese operating company contractually controlled by Datasea, has entered into a cooperation agreement with Hangzhou Chongda Technology Co., Ltd. (“Chongda”) to increase…

Wednesday Feb 14, 2024 - 9:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer's and age-related macular degeneration. Highlights of the report included that the company closed the 2023…

Tuesday Feb 13, 2024 - 12:34 pm

InvestorNewsBreaks – Renovaro Inc. (NASDAQ: RENB) Fusing AI and Biotech to Accelerate Personalized Medicine, GEDiCube, Cyclomics Enter LOI to ‘Change the Field’

Renovaro (NASDAQ: RENB) today announced the completion of its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, marking a new era in healthcare innovation. According to the announcement, the two subsidiaries will be under the…

Tuesday Feb 13, 2024 - 9:39 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q2 2024 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin…

Monday Feb 12, 2024 - 2:52 pm

InvestorNewsBreaks — Astiva Health Marks Pivotal Phase in Transforming Healthcare Delivery

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector in a recent episode of the Bell2Bell Podcast. “The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology. During the interview,…

Friday Feb 09, 2024 - 2:58 pm

InvestorNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the…

Friday Feb 09, 2024 - 11:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles,…

Thursday Feb 08, 2024 - 3:03 pm

InvestorNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering

Revelation Biosciences (NASDAQ: REVB), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, recently announced the closing of its public offering. The offering consisted of 128,470 shares of the company’s common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its…

Wednesday Feb 07, 2024 - 1:01 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Introducing Breakthrough Technology, Potential ‘Game Changer’ for the Cannabinoid Industry

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM). Its subsidiary, AgLAB Inc., has breakthrough mass spectrometry technology in its AgLAB-1000-D2 mass spectrometer, a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials, and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed…

Tuesday Feb 06, 2024 - 2:43 pm

InvestorNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for a patent application related to the use of Lomecel-B(TM) in Aging-related Frailty sufferers receiving vaccines for conditions such as…

Tuesday Feb 06, 2024 - 11:52 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD…

Tuesday Feb 06, 2024 - 11:28 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb.…

Tuesday Feb 06, 2024 - 9:45 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases,…

Monday Feb 05, 2024 - 11:39 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca's Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2…

Monday Feb 05, 2024 - 11:08 am

InvestorNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Announces Upcoming Launch and Expansion of OPKO Health-Branded Storefront

NextPlat (NASDAQ: NXPL, NXPLW), a global e-Commerce provider, is preparing for the launch of its exclusive OPKO Health-branded storefront on Alibaba Group Holding Limited's ("Alibaba")(NYSE: BABA) Tmall Global in China. The move follows the company’s receipt of the initial set of approvals required to operate the store in the country. “We are pleased to reach this strategic milestone with our partners OPKO and Alibaba because…

Friday Feb 02, 2024 - 12:30 pm

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients

Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies,…

Friday Feb 02, 2024 - 10:27 am

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business days and subsequently revert to trading under its historic symbol…

Tuesday Jan 30, 2024 - 12:38 pm

InvestorNewsBreaks — Astiva Health Featured in Bell2Bell Podcast

Astiva Health, which is rapidly making its mark in the Medicare Advantage Prescription Drug (“MAPD”) sector with its commitment to transforming personalized and comprehensive healthcare, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Dr. Tri T. Nguyen, the co-founder and CEO of Astiva Health, joined the program to…

Tuesday Jan 30, 2024 - 12:03 pm

InvestorNewsBreaks – IBN, BioMedWire to Serve as Official Media Partners for BioPharma Nexus Events

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, has announced its media collaboration with BioPharma Nexus for upcoming events in 2024. BioMedWire, a specialized communications platform dedicated to the life sciences sector and a vital component of IBN’s Dynamic Brand Portfolio, will also serve as an official media partner for the events. Renowned for its expertise in life sciences, BioPharma Nexus organizes industry leading…

Tuesday Jan 30, 2024 - 9:48 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Names New Board Member, Reports on Corporate Updates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has appointed Dr. Sanjiv Chopra to its board of directors. According to the announcement. Chopra will be replacing Nitin Kaushal, who resigned from his position. A professor of medicine and former faculty dean for continuing medical education at Harvard Medical School, Dr. Sanjiv…

Tuesday Jan 30, 2024 - 9:42 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions